Digital Workshop: Autodoc Launches the Autodoc Club Innovative Platform
29.10.2019 10:00:00 EET | Business Wire | Press release
Autodoc, the benchmark in the online retailing for car spare parts in Europe, is now offering its customers and interested parties an innovative platform for the maintenance of their own car under the name “Autodoc Club”. Thanks to its features, it is unique on the market. The platform, which is available in 26 European countries, contains over 1,300 professional PDF repair instructions in all national languages, plus 2,240 detailed video tutorials. In addition, there is a whole range of other useful functions, such as the integrated maintenance protocol for your own car. This opens up new possibilities for planning repairs and controlling costs. The Autodoc Club app is scheduled for release for Android and iOS operating systems at the beginning of 2020, and bundles on mobile devices all the Club website functions for smartphone and tablet users.
One-stop shop for advice, service and parts
Autodoc’s “Autodoc Club” now offers its customers an innovative platform that provides a wide range of services related to the repair and maintenance of cars. In addition to instructions in the form of PDFs and video tutorials, Autodoc Club offers various other features: users can not only store their car model in their profile, but also keep a maintenance log, receive reminders for the replacement of consumables or save workshop information.
The main component of the new Autodoc Club is a collection of over 1,300 PDF repair manuals and 2,240 video tutorials on individual repairs. A search function enables the customer to find the right manual for their car for the upcoming project. If a manual is not yet available, it can be requested directly from the Autodoc specialists.
Professional advice and convenient purchase of spare parts
The instructions provide direct access to the Autodoc online shop. The user can order all required parts conveniently in the spare parts dealer’s online shop. If a tool is missing, it can also be ordered directly in the online shop. In case of questions regarding repairs or spare parts, the customer can contact specialists such as car mechanics or technicians directly in the forum at any time. Autodoc Club therefore offers an integrated one-stop solution for car owners who want to repair their car themselves or obtain comprehensive information and buy spare parts directly and inexpensively.
“For the layman, car parts are mostly products that require explanation. From our experience, we know that many customers often have questions and need advice from experts. We now offer such support with the easy-to-use and integrated Autodoc Club platform. Every car owner can see how a repair is done, get help and decide for themselves what support they need from their local workshop. In any case, they can always order parts and tools conveniently from the Autodoc online shop without having to search the Internet for them”, explains Autodoc Managing Director, Alexej Erdle.
Free platform for car-related services
Additional features such as a maintenance log and a reminder function for changing consumables round off the offer and also help to avoid unnecessary costs. As a result, your car always stays in top condition. In the personal area, the user can also store vehicle documents, vehicle insurance policies and their own notes, so that all documents relating to their car are always at hand. And from the beginning of 2020, this will also be possible when on the go and travelling using your smartphone.
The use of the platform is unlimited and independent of placing an order. The creation of a free user account is only required for the personal assistant. Existing registration data for the Autodoc online shop also work on the new portal. Any car data already entered in the store account will also be transferred automatically when registering for Autodoc Club with the same account.
About Autodoc
Autodoc is Europe's leading online dealer for car spare parts. As the fastest-growing company in this sector with sales growth of 63% in the financial year 2018 to around EUR 415 million (2017: EUR 254 million), Autodoc aims to further expand its position. Thanks to its successful expansion, Autodoc is now represented in 25 other European countries in addition to Germany. Autodoc pursues a strong customer focus through social media campaigns, technical support in the respective national language and a current demand-oriented range of almost 2.5 million products from 545 brand manufacturers for 128 car brands. Autodoc GmbH is based in the Berlin district of Lichtenberg and is fully owner-managed. In addition to its headquarters, the company opened a representative office on Kurfürstendamm in May 2019.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191029005090/en/
Contact information
Thomas Casper
Head of Press and Public Relations & Communication
Tel.: +49-30-2084-78-237
E-mail: t.casper@autodoc.eu
www.autodoc.de
cometis AG
Matthias Kunz
Tel.: +49-611-20-585-564
kunz@cometis.de
www.cometis.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom